Clinical trial NCT02361957: The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients
Official title: The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: NA
Conditions: Ulcerative Colitis
Lead sponsor: Wageningen University
Sponsor class: OTHER
First posted: 2015-02-12
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: RATIONALE: The underlying etiology in inflammatory bowel diseases such as Ulcerative Colitis is not yet fully understood. Studies suggest a relation between higher intestinal permeability and aberrant changes of the epithelium. Dysbiosis of the intestinal microbiota might be the cause. Probiotics may restore the balance of the intestinal microbiota. In theory this could improve intestinal permeability and therefore reduce disease activity and maintain remission in patients with Ulcerative Colitis.

OBJECTIVE: To investigate whether a specifically designed multispecies probiotic mixture (ecologic 825®), as adjuvant therapy, can contribute to an improvement of intestinal permeability, microbiota composition, disease activity and inflammatory markers in ulcerative colitis.

STUDY DESIGN: 12-wk placebo-controlled randomized double-blind intervention with 2 parallel arms.

STUDY POPULATION: Adults diagnosed with left sided Ulcerative Colitis or Pancolitis in remission or mild stage of the disease. For inclusion of the patients the Patient Simple Clinical Colitis Activity Index (P-SCCAI) will be used.

INTERVENTION: Patients will receive either two daily dosages of 3 g of Ecologic® 825 or two daily doses of 3 g of the placebo, containing only the carrier material (both produced by Winclove Probiotics).

MAIN STUDY PARAMETERS/ENDPOINTS: Main study parameter is intestinal permeability measured by several techniques: the lactulose/mannitol absorption test (L/M test), LPS levels in blood serum and faecal zonulin. Secondary, inflammation will be measured from faecal calprotectin and blood c-reactive protein (CRP) levels. Furthermore samples will be stored to measure cytokine concentrations in serum and to analyse the microbial composition of the faecal samples using the HITchip. For the disease related quality of life the irritable bowel disease questionnaire (IBD-Q) and SF-36 will be used. All parameters will be measured at three time points; t=0, t=6 and t=12 weeks.


Eligibility criteria: Inclusion Criteria:

* Diagnosed Ulcerative Colitis (left sided UC or pancolitis)
* Age 18-65 (because microbiota change at older age)
* Stable disease activity (clinical remission with CRP levels \<10mg/L and calprotectin \<100 ug/g) as measured at baseline
* Mild disease activity (P-SCCAI \<5)
* Mesalazine medication as only medication for UC with a maximum intake of 2.4 g/day

Exclusion Criteria:

* History of intestinal surgery that might interfere with the outcome of the study
* Diabetes Mellitus (medication dependent)
* Current use of antibiotics
* Current use of corticosteroids (30 days prior to the first baseline measurement).
* Treatment with other medication besides mesalazine (NSAIDs, topical or systemic steroids, immunosuppressive drugs or aspirin) one week prior the first baseline measurement.
* Use of other pre- and probiotics and not willing to stop these 2 weeks before the intervention period
* Hypersensitivity or allergy to milk protein, soy protein and gluten
* Alcohol abuse (male more than 14 servings a week, female more than 7 servings a week)
* Female patients: currently pregnant or breast-feeding or intending to become pregnant during the study
* Patients foreseen to need GI surgery during the study period
* Patients with a history of cancer

Primary outcomes:
measure: Intestinal permeability measured by the Lactulose Mannitol test (L/M test)
timeFrame: 12 weeks
Secondary outcomes:
measure: blood CRP levels
timeFrame: 6 and 12 weeks
measure: fecal calprotectin levels
timeFrame: 6 and 12 weeks
measure: Quality of life (measured by IBD-Q and SF36)
timeFrame: 6 and 12 weeks
measure: Intestinal permeability measured by the Lactulose Mannitol test (L/M test)
timeFrame: 6 weeks
measure: Lipopolysaccharides levels in blood
timeFrame: 6 and 12 weeks
measure: Intestinal permeability measured by faecal zonulin levels
timeFrame: 6 and 12 weeks
measure: microbiota composition
timeFrame: 6 and 12 weeks
measure: interferon gamma levels
timeFrame: 6 and 12 weeks
Other outcomes:
Locations:
city: Ede
country: Netherlands
facility: Gelderse Vallei Hospital
Study officials:
affiliation: Wageningen UR
name: Nicole De Roos, PhD
role: PRINCIPAL_INVESTIGATOR
References: